Uncategorized
Biopharma Company Sues DEA for ‘Unjustified Delays’ in Approving Cannabis Research
A biopharmaceutical company is suing the Drug Enforcement Administration (DEA) over what it called unjustified delays to its application to launch clinical trials into cannabis treatments for Multiple Sclerosis (MS) and Huntington’s Disease (HD).
